Novartis AG (Novartis AG) FCF Margin % : 9.15% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Novartis AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Novartis AG's Free Cash Flow for the three months ended in Mar. 2024 was $1,109 Mil. Novartis AG's Revenue for the three months ended in Mar. 2024 was $12,120 Mil. Therefore, Novartis AG's FCF Margin % for the quarter that ended in Mar. 2024 was 9.15%.

As of today, Novartis AG's current FCF Yield % is 4.93%.

The historical rank and industry rank for Novartis AG's FCF Margin % or its related term are showing as below:

NVSEF' s FCF Margin % Range Over the Past 10 Years
Min: 16.66 Med: 23.57 Max: 28.46
Current: 20.33

During the past 13 years, the highest FCF Margin % of Novartis AG was 28.46%. The lowest was 16.66%. And the median was 23.57%.

NVSEF's FCF Margin % is ranked better than
91.13% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.695 vs NVSEF: 20.33

Novartis AG FCF Margin % Historical Data

The historical data trend for Novartis AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG FCF Margin % Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

23.35

22.18

28.46

27.60

25.09

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															23.25	18.51	38.83	14.98	9.15

Competitive Comparison of Novartis AG's FCF Margin %

For the Drug Manufacturers - General subindustry, Novartis AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novartis AG's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Novartis AG's FCF Margin % falls into.

Novartis AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Novartis AG's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	11705	/	46660
	=	25.09 %

Novartis AG's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	1109	/	12120
	=	9.15 %

Novartis AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of Novartis AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.